ANTIBODIES

CancerTools.org: The home for cancer research tools

Back

Anti-Cytochrome P450 7B1 [M17-P3F2]

Cat. #152117

Tool name: Anti-Cytochrome P450 7B1 [M17-P3F2]
Clone: M17-P3F2
Tool type: Antibodies
Tool sub-type: Primary antibody
Class: Monoclonal
Conjugate: Unconjugated
Reactivity: Human
Host: Mouse
Application: ELISA ; IHC ; WB
Strain: Balb/c
Description: Defects in CYP7B1 are the cause of spastic paraplegia autosomal recessive type 5A (SPG5A) [MIM:270800]. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Defects in CYP7B1 are the cause of congenital bile acid synthesis defect type 3 (CBAS3) [MIM:613812]. Clinical features include severe cholestasis, cirrhosis and liver synthetic failure. Hepatic microsomal oxysterol 7-alpha-hydroxylase activity is undetectable.
Immunogen: Ovalbumin-conjugated synthetic peptide IQYPDSDVL (C-terminal sequence)
Isotype: IgG1 lambda
Research area: Cancer; Tissue-specific biology; Cell signaling and signal transduction; Metabolism; Neurobiology
Myeloma used: P3X63Ag8.653

Target: Cytochrome P450, family 7, subfamily B, polypeptide 1 (CYP7B1)
Target background: Defects in CYP7B1 are the cause of spastic paraplegia autosomal recessive type 5A (SPG5A) [MIM:270800]. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Defects in CYP7B1 are the cause of congenital bile acid synthesis defect type 3 (CBAS3) [MIM:613812]. Clinical features include severe cholestasis, cirrhosis and liver synthetic failure. Hepatic microsomal oxysterol 7-alpha-hydroxylase activity is undetectable.

• Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer.
• Swan et al. 2016. Oncotarget. :. PMID: 27341022.

£ 300
This fee is applicable only for non-profit organizations

Quantity:

For any enquiries, please, contact us .